Elypta
Precision Medicine · Molecular Diagnostics
$6.5Mlatest round · Seed · Jan 2020 · 6 yr ago
5backers · Chalmers Ventures, Industrifonden
$2.8Mgrants · 2 grants · CORDIS
50+team · employees, estimated range
Overview
Early detection of cancer starts with knowing who is at risk. Elypta provides the missing dynamic biological signal that unlocks risk testing at scale.
Funding and backers
Total raised
$6.5M
3 rounds on record
Latest round
$6.5M
Seed · Jan 2020 · 6 yr ago
Team
51-200
employees, estimated range
Grants
$2.8M
2 grants · CORDIS
Backers
5
Chalmers Ventures, Industrifonden
The money's age
Long since its last round
81 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 1, 2025
Won a grant $292k · CORDIS
Jan 23, 2020
Raised a round Seed $6.5M · led by Industrifonden · PRNewswire
May 1, 2019
Won a grant $2.5M · CORDIS
Tractionpublic signals, read monthly
Web presence
top 10%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | May 2025 | $292k | — | CORDIS |
| Seed | Jan 2020 | $6.5M | Industrifonden lead | PRNewswire |
| Grant | May 2019 | $2.5M | — | CORDIS |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Liquid biopsy for the early detection of gastric cancer. With only a blood sample, and even without symptoms, detects a tumor in the…
The key to managing cancer is early detection. ClearNote Health makes this possible by finding signals of cancer in the blood early.
Geneseeq is a Chinese precision oncology company applying high-throughput sequencing to clinical genetic testing for cancer patients. Its…
EX MARKS THE SPOT, AI CRACKS THE CODE. Exai is harnessing RNA for early, accurate cancer detection and profound insights from just a blood…
Combining the power of liquid biopsy and AI-driven epigenetics, we deliver accurate cancer detection. Our approach transforms diagnostics…
Altum Sequencing delivers ultra-sensitive ctDNA detection for cancer monitoring and MRD assessment. Precision liquid biopsy solutions for…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Navigare VenturesVia a fund
Nina CapitalVia a fund
NorrskenVia a fund
IndustrifondenVia a fund
Chalmers VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune
Key market opportunities in liquid biopsy for early cancer detection include increasing demand for non-invasive diagnosis, driven by rising cancer cases and precision oncology trends. Advancements in multi-cancer assays, minimal residual disease detection
Read more
Report
Elypta's urine-based test shows recurrence of kidney cancer
Elypta AB's urine-based test correctly identified 90% of patients whose kidney cancer had returned, according to results from an ongoing study. The company's metabolism-based liquid biopsy platform, which measures glycosaminoglycan biomarkers to detect ca
Read more
Report
Chalmers Ventures investerar i cancerdiagnostikbolaget Elypta
Chalmers Ventures följdinvesterar i portföljbolaget Elypta som stänger en finansieringsrunda för att nå viktiga milstenar i sin utveckling. Elypta utvecklar...
Read more
Report
Elypta launches Multi-Cancer Early Detection screening study measuring metabolic GAGome levels in asymptomatic adults
Stockholm, Feb 15, 2022: Swedish molecular diagnostic company Elypta announces today the launch of
Read more
Report
Elypta extends range of GAGome-based liquid biopsy applications San Raffaele initiates new AUR93A muscle-invasive bladder cancer (MICB) study
Stockholm, Dec 08, 2021: Elypta announces the enrollment of the first patient in the newly
Read more
Report
Chalmersbolaget Elypta AB tar in 65 miljoner kronor för utveckling av unik cancerdiagnostik
Elypta utvecklar ett nytt banbrytande urinprov som möjliggör tidig upptäckt av cancer genom tätare uppföljning vid behandling. Med hjälp av AI finns...
Read more
Report
Elypta Raises €6 Million in a Late Seed Round Led by Industrifonden
/PRNewswire/ -- Elypta, the Swedish molecular diagnostics firm pioneering metabolism-based liquid biopsies, has raised €6.1 million in a late seed funding...
Read more
Report